Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Youyi Fong

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
NPJ Vaccines|March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccineDavid Benkeser, Youyi Fong, Holly E Janes, et al.
Science (New York, N.Y.)|November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialPeter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
The Journal of Clinical Investigation|June 9, 2015
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmissionSallie R Permar, Youyi Fong, Nathan Vandergrift, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy TrialPeter B Gilbert, David C Montefiori, Adrian McDermott, et al.
Nature Communications|September 11, 2024
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trialBo Zhang, Youyi Fong, Jonathan Fintzi, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Science Translational Medicine|April 19, 2023
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trialDavid Benkeser, David C Montefiori, Adrian B McDermott, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
NPJ Vaccines|March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccineDavid Benkeser, Youyi Fong, Holly E Janes, et al.
Science (New York, N.Y.)|November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialPeter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
The Journal of Clinical Investigation|June 9, 2015
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmissionSallie R Permar, Youyi Fong, Nathan Vandergrift, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy TrialPeter B Gilbert, David C Montefiori, Adrian McDermott, et al.
Nature Communications|September 11, 2024
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trialBo Zhang, Youyi Fong, Jonathan Fintzi, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Science Translational Medicine|April 19, 2023
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trialDavid Benkeser, David C Montefiori, Adrian B McDermott, et al.
Pageof 11